Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × Clinical Trials, Phase I as Topic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡